Anaptysbio (ANAB) Free Cash Flow Growth (1y) (2017 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Free Cash Flow Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 38.94% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 96.00% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 152.82% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 31.57% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 58.53% |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - | -141.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -141.66% |
| Dec 31, 2025 | 246.40% |
| Sep 30, 2025 | -170.30% |
| Jun 30, 2025 | -88.63% |
| Mar 31, 2025 | 71.20% |
| Dec 31, 2024 | -93.29% |
| Sep 30, 2024 | 72.36% |
| Jun 30, 2024 | 16.58% |
| Mar 31, 2024 | -50.67% |
| Dec 31, 2023 | -218.87% |
| Sep 30, 2023 | -105.85% |
| Jun 30, 2023 | -5.67% |
| Mar 31, 2023 | -17.44% |
| Dec 31, 2022 | 57.10% |
| Sep 30, 2022 | -147.94% |
| Jun 30, 2022 | -377.55% |
| Mar 31, 2022 | 10.42% |
| Dec 31, 2021 | -167.93% |
| Sep 30, 2021 | 58.03% |
| Jun 30, 2021 | 144.32% |